Skip to main content Accessibility help

We use s to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept s or find out how to .


The different trajectories of antipsychotic response: antipsychotics versus placebo

  • T. R. Marques (a1), T. Arenovich (a2), O. Agid (a2), G. Sajeev (a2), B. Muthén (a3), L. Chen (a4), B. J. Kinon (a4) and S. Kapur (a1)...

It is generally accepted that antipsychotics are more effective than placebo. However, it remains unclear whether antipsychotics induce a pattern or trajectory of response that is distinct from placebo. We used a data-driven technique, called growth mixture modelling (GMM), to identify the different patterns of response observed in antipsychotic trials and to determine whether drug-treated and placebo-treated subjects show similar or distinct patterns of response.


We examined data on 420 patients with schizophrenia treated for 6 weeks in two double-blind placebo-controlled trials using haloperidol and olanzapine. We used GMM to identify the optimal number of response trajectories; to compare the trajectories in drug-treated versus placebo-treated patients; and to determine whether the trajectories for the different dimensions (positive versus negative symptoms) were identical or different.


Positive symptoms were found to respond along four distinct trajectories, with the two most common trajectories (‘Partial responder’ and ‘Responder’) accounting for 70% of the patients and seen proportionally in both drug- and placebo-treated. The most striking drug–placebo difference was in the ‘Dramatic responders’, seen only among the drug-treated. The response of negative symptoms was more modest and did not show such distinct trajectories.


Trajectory models of response, rather than the simple responder/non-responder dichotomy, provide a better statistical account of how antipsychotics work. The ‘Dramatic responders’ (those showing >70% response) were seen only among the drug-treated and make a significant contribution to the overall drug–placebo difference. Identifying and studying this subset may provide specific insight into antipsychotic action.

Corresponding author
*Address for correspondence: S. Kapur, M.B.B.S., Ph.D., F.R.C.P.C., Dean and Professor, PO Box 053, Institute of Psychiatry, King's College London, De Crespigny Park, London SE5 8AF, UK. (Email: [email protected])
Hide All
Agid, O, Kapur, S, Arenovich, T, Zipursky, RB (2003). Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Archives of General Psychiatry 60, 12281235.
Agid, O, Potkin, S, Remington, G, Kapur, S, Watsky, E, Vanderburg, D, Siu, C (2010). Meta-analysis of placebo response in antipsychotic trials. APA Annual Meeting, New Orleans, May 2010.
Beasley, CM Jr., Sanger, T, Satterlee, W, Tollefson, G, Tran, P, Hamilton, S (1996 a). Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berlin) 124, 159167.
Beasley, CM Jr., Tollefson, G, Tran, P, Satterlee, W, Sanger, T, Hamilton, S (1996 b). Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14, 111123.
Garver, DL, Holcomb, JA, Christensen, JD (2000). Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. Journal of Clinical Psychiatry 61, 964972; quiz 973.
Kapur, S, Arenovich, T, Agid, O, Zipursky, R, Lindborg, S, Jones, B (2005). Evidence for onset of antipsychotic effects within the first 24 hours of treatment. American Journal of Psychiatry 162, 939946.
Kinon, BJ, Chen, L, Ascher-Svanum, H, Stauffer, VL, Kollack-Walker, S, Sniadecki, JL, Kane, JM (2008). Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia Research 102, 230240.
Leucht, S, Busch, R, Hamann, J, Kissling, W, Kane, JM (2005). Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biological Psychiatry 57, 15431549.
Leucht, S, Kane, JM, Etschel, E, Kissling, W, Hamann, J, Engel, RR (2006). Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 31, 23182325.
Levine, SZ, Rabinowitz, J (2008). Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophrenia Bulletin 36, 624632.
Muthén, B, Brown, HC (2009). Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling. Statistics in Medicine 28, 33633385.
Muthén, B, Brown, CH, Leuchter, A, Hunter, A (in press). General approaches to analysis of course: applying growth mixture modeling to randomized trials of depression medication. In Causality and Psychopathology: Finding the Determinants of Disorders and their Cures (ed. Shrout, P. E.). American Psychiatric Publishing: Washington, DC.
Muthén, B, Brown, CH, Masyn, K, Jo, B, Khoo, ST, Yang, CC, Wang, CP, Kellam, S, Carlin, J, Liao, J (2002). General growth mixture modeling for randomized preventive interventions. Biostatistics (Oxford, England) 3, 459475.
Muthén, B, Muthén, L (2007). M: Statistical Analysis with Latent Variables: User's Guide, 5th edn. Muthén and Muthén: Los Angeles, CA.
Muthén, B, Shedden, K (1999). Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics 55, 463469.
Overall, JE, Gorham, DR (1962). The Brief Psychiatric Rating Scale. Psychological Reports 10, 799812.
Quitkin, FM, Rabkin, JG, Ross, D, Stewart, JW (1984). Identification of true drug response to antidepressants. Use of pattern analysis. Archives of General Psychiatry 41, 782786.
Rothschild, R, Quitkin, FM (1992). Review of the use of pattern analysis to differentiate true drug and placebo responses. Psychotherapy and Psychosomatics 58, 170177.
Stassen, HH, Angst, J, Hell, D, Scharfetter, C, Szegedi, A (2007). Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. Journal of Clinical Psychiatry 68, 11951205.
Stassen, HH, Delini-Stula, A, Angst, J (1993). Time course of improvement under antidepressant treatment: a survival-analytical approach. European Neuropsychopharmacology 3, 127135.
Stewart, JW, Quitkin, FM, McGrath, PJ, Amsterdam, J, Fava, M, Fawcett, J, Reimherr, F, Rosenbaum, J, Beasley, C, Roback, P (1998). Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Archives General Psychiatry 55, 334343.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Psychological Medicine
  • ISSN: 0033-2917
  • EISSN: 1469-8978
  • URL: /core/journals/psychological-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed